Physician profile
Michael J Spence
NPI 1558388157
$1,685.76
in general payments reported to CMS, 2019-2025
22 companies · $18.37 in 2025
The $18.37 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $284 · 2021: $306 · 2022: $402 · 2023: $64.05 · 2025: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.99 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $291.67 | 2019-2021 | |
| Horizon Therapeutics Plc | $172.61 | 2020-2021 | |
| Abbvie INC. | $126.31 | 2021-2025 | Qulipta |
| Collegium Pharmaceutical, INC. | $123.19 | 2019-2023 | Xtampza |
| Allergan, INC. | $113.40 | 2019 | |
| Biodelivery Sciences International, INC. | $107.35 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $106.75 | 2019-2022 | |
| Zyla Life Sciences, INC. | $65.90 | 2019-2020 | |
| Ibsa Pharma INC. | $33.25 | 2021-2022 | |
| Shionogi INC | $31.37 | 2019 | |
| Daiichi Sankyo INC. | $27.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.05 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.56 | 2023 | Horizant |
| Mdd US Operations, LLC | $15.78 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $14.51 | 2021 | |
| Assertio Therapeutics, INC. | $14.43 | 2019 | |
| Electronic Waveform Lab, INC. | $13.84 | 2019 | |
| Pfizer INC. | $12.29 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $11.49 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.43 | 2019 | |
| Boston Scientific Corporation | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.